187 related articles for article (PubMed ID: 23610071)
41. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
42. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
43. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
[TBL] [Abstract][Full Text] [Related]
44. p53 protein aggregation promotes platinum resistance in ovarian cancer.
Yang-Hartwich Y; Soteras MG; Lin ZP; Holmberg J; Sumi N; Craveiro V; Liang M; Romanoff E; Bingham J; Garofalo F; Alvero A; Mor G
Oncogene; 2015 Jul; 34(27):3605-16. PubMed ID: 25263447
[TBL] [Abstract][Full Text] [Related]
45. Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules.
Li N; Jiang P; Du W; Wu Z; Li C; Qiao M; Yang X; Wu M
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12851-6. PubMed ID: 21768358
[TBL] [Abstract][Full Text] [Related]
46. Epstein-Barr virus-encoded LMP1 triggers regulation of the ERK-mediated Op18/stathmin signaling pathway in association with cell cycle.
Lin X; Tang M; Tao Y; Li L; Liu S; Guo L; Li Z; Ma X; Xu J; Cao Y
Cancer Sci; 2012 Jun; 103(6):993-9. PubMed ID: 22417000
[TBL] [Abstract][Full Text] [Related]
47. Rlim, an E3 ubiquitin ligase, influences the stability of Stathmin protein in human osteosarcoma cells.
Chen X; Shen J; Li X; Wang X; Long M; Lin F; Wei J; Yang L; Yang C; Dong K; Zhang H
Cell Signal; 2014 Jul; 26(7):1532-8. PubMed ID: 24686088
[TBL] [Abstract][Full Text] [Related]
48. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model.
Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M
Oncogene; 2014 Feb; 33(7):882-90. PubMed ID: 23396365
[TBL] [Abstract][Full Text] [Related]
49. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.
Liu K; Ling S; Lin WC
Mol Cell Biol; 2011 Nov; 31(22):4464-81. PubMed ID: 21930790
[TBL] [Abstract][Full Text] [Related]
50. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
51. Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells.
Zerbini LF; Wang Y; Correa RG; Cho JY; Libermann TA
Cell Cycle; 2005 Sep; 4(9):1247-53. PubMed ID: 16082226
[TBL] [Abstract][Full Text] [Related]
52. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
53. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
[TBL] [Abstract][Full Text] [Related]
54. Growth arrest in ovarian cancer cells by hTERT inhibition short-hairpin RNA targeting human telomerase reverse transcriptase induces immediate growth inhibition but not necessarily induces apoptosis in ovarian cancer cells.
Luo Y; Yi Y; Yao Z
Cancer Invest; 2009 Dec; 27(10):960-70. PubMed ID: 19909010
[TBL] [Abstract][Full Text] [Related]
55. Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway.
Wu SZ; Xu HC; Wu XL; Liu P; Shi YC; Pang P; Deng L; Zhou GX; Chen XY
Phytomedicine; 2019 Jun; 59():152895. PubMed ID: 30913453
[TBL] [Abstract][Full Text] [Related]
56. Modulation of Janus kinase 2 by p53 in ovarian cancer cells.
Reid T; Jin X; Song H; Tang HJ; Reynolds RK; Lin J
Biochem Biophys Res Commun; 2004 Aug; 321(2):441-7. PubMed ID: 15358195
[TBL] [Abstract][Full Text] [Related]
57. The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study.
Kamińska I; Bar JK
Pharmacol Rep; 2018 Jun; 70(3):570-576. PubMed ID: 29684847
[TBL] [Abstract][Full Text] [Related]
58. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
PLoS One; 2015; 10(5):e0125714. PubMed ID: 25933027
[TBL] [Abstract][Full Text] [Related]
60. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
